Pain and mobility issues common with moderate hemophilia: Study
Progressive joint disease caused by repeat bleeds, a condition known as hemophilic arthropathy, affects people with moderate hemophilia in…
Articles by Patricia Inácio, PhD
Risk of developing inhibitors varies depending on therapy type: Study
The development of neutralizing antibodies, or inhibitors, against the clotting factor in replacement therapies administered to people…
FEIBA found to be safe, effective in severe hemophilia with inhibitors
When given as a prophylactic, or preventive therapy, or on an on-demand basis, FEIBA (factor eight inhibitor bypassing activity)…
FVIII infusion resolves rare GI bleeding in hemophilia A patient
A 48-year-old man with severe hemophilia A developed a rare intramural hematoma with blood leaking into one of the…
Hemophilia patients in the Netherlands very satisfied with care
Most people with hemophilia responding to a survey in the Netherlands were generally satisfied with their treatment care. Patients’…
Hemophilia doesn’t protect against severe COVID-19 outcomes: Study
People with hemophilia showed no heightened protection against COVID-19 severity or mortality, a large retrospective U.S. outcomes study found.
Early milestone in work for hem A gene-editing tool met: 2seventy bio
2seventy bio announced that it has achieved a key preclinical milestone under its joint program with Novo Nordisk…
Dosing complete in Phase 3 trial of Belief BioMed’s gene therapy candidate
Patient dosing has been completed in a registrational Phase 3 clinical trial in China testing BBM-H901, Belief BioMed‘s (BBM)’s…
America’s Blood Centers organizes first Blood Advocacy Week
The first Blood Advocacy Week, which promotes activities to showcase the importance of maintaining a safe and continuous blood…
WHO physical activity goals unmet in many teens with hemophilia A
Teens and young adults with moderate and severe hemophilia A on continuous preventive treatment show levels of physical activity…